Skip to content
Screener

Amphastar Pharmaceuticals AMPH Q4 2025 Annual earnings

Reported February 26, 2026 · After market close

Revenue$183.1MMiss by $5.7M
EPS$0.73Miss by $0.17
Revenue estimate$188.8M
EPS estimate$0.90

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$197.9M
EPS estimate$0.86

Financials

Q4 2025

Income statement

See full
Revenue$183.1M-1.8%
Gross profit$85.7M-1.1%
Operating income$35.6M-21.1%
Net income$24.4M-35.7%
EPS (diluted)$0.51-31.1%

Balance sheet

See full
Cash & equivalents$170.2M+12.2%
Total debt$656.3M+0.8%
Total assets$1.6B+3.3%

Cash flow

See full
Operating cash flow$32.9M+13.2%
CapEx$8.3M-33.3%
Free cash flow$24.6M+48.0%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1.23B-31.1%
Enterprise value$1.72B-24.9%
P/E12.5×+1.4×
P/S1.7×-0.7×

Profitability

See full
Gross margin49.5%-1.6pp
Operating margin19.5%-8.6pp
Net margin13.6%-8.2pp
FCF margin16.8%-6.7pp

Returns & leverage

See full
Current ratio4×+0.9×

Segments

By geography

See full
US$171.6M-2.0%
FR$10.6M+15.0%
CN$925.0K-57.8%

FAQ

When did Amphastar Pharmaceuticals report Q4 2025 earnings?
Amphastar Pharmaceuticals (AMPH) reported Q4 2025 earnings on February 26, 2026 after market close.
What were Amphastar Pharmaceuticals's Q4 2025 revenue and EPS?
Amphastar Pharmaceuticals reported revenue of $183.1M and eps of $0.73 for Q4 2025.
Did Amphastar Pharmaceuticals beat estimates in Q4 2025?
Revenue missed the consensus estimate of $188.8M by $5.7M. EPS missed the consensus estimate of $0.90 by $0.17.
How did Amphastar Pharmaceuticals's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 1.8% from $186.5M a year earlier and eps declined 20.7% from $0.92.
Where can I find Amphastar Pharmaceuticals's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001297184-26-000007) and the 10-K periodic report (0001297184-26-000009) directly on SEC EDGAR. The filing index links above go to sec.gov.